Overview

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Ophthotech Corporation
Treatments:
Bevacizumab
Platelet-derived growth factor BB